Clinical Trial Update: Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in Canada

View source ↗

Summary

This observational study evaluates disease course and outcomes in Canadian patients with idiopathic pulmonary fibrosis treated with pirfenidone (Esbriet).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Esbriet (pirfenidone)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Idiopathic Pulmonary Fibrosis | Status: COMPLETED